BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: van Aalten SM, Verheij J, Terkivatan T, Dwarkasing RS, de Man RA, Ijzermans JN. Validation of a liver adenoma classification system in a tertiary referral centre: implications for clinical practice. J Hepatol. 2011;55:120-125. [PMID: 21145863 DOI: 10.1016/j.jhep.2010.10.030] [Cited by in Crossref: 74] [Cited by in F6Publishing: 59] [Article Influence: 6.2] [Reference Citation Analysis]
Number Citing Articles
1 Bellamy COC, Maxwell RS, Prost S, Azodo IA, Powell JJ, Manning JR. The value of immunophenotyping hepatocellular adenomas: consecutive resections at one UK centre: Hepatocellular adenomas. Histopathology 2013;62:431-45. [DOI: 10.1111/his.12011] [Cited by in Crossref: 32] [Cited by in F6Publishing: 21] [Article Influence: 3.2] [Reference Citation Analysis]
2 Rodrigues BT, Mei SLCY, Fox A, Lubel JS, Nicoll AJ. A systematic review on the complications and management of hepatic adenomas: a call for a new approach. Eur J Gastroenterol Hepatol 2020;32:923-30. [PMID: 32433418 DOI: 10.1097/MEG.0000000000001766] [Reference Citation Analysis]
3 Agrawal S, Agarwal S, Arnason T, Saini S, Belghiti J. Management of Hepatocellular Adenoma: Recent Advances. Clin Gastroenterol Hepatol. 2015;13:1221-1230. [PMID: 24909909 DOI: 10.1016/j.cgh.2014.05.023] [Cited by in Crossref: 55] [Cited by in F6Publishing: 40] [Article Influence: 6.9] [Reference Citation Analysis]
4 Breuker C, Planque C, Rajabi F, Nault JC, Couchy G, Zucman-Rossi J, Evrard A, Kantar J, Chevet E, Bioulac-Sage P, Ramos J, Assenat E, Joubert D, Pannequin J, Hollande F, Pascussi JM. Characterization of a novel PXR isoform with potential dominant-negative properties. J Hepatol 2014;61:609-16. [PMID: 24798619 DOI: 10.1016/j.jhep.2014.04.030] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
5 Bioulac-Sage P, Taouji S, Possenti L, Balabaud C. Hepatocellular adenoma subtypes: the impact of overweight and obesity. Liver Int. 2012;32:1217-1221. [PMID: 22429502 DOI: 10.1111/j.1478-3231.2012.02786.x] [Cited by in Crossref: 86] [Cited by in F6Publishing: 71] [Article Influence: 8.6] [Reference Citation Analysis]
6 Miller GC, Campbell CM, Manoharan B, Bryant R, Cavallucci D, O'Rourke N, Clouston AD. Subclassification of hepatocellular adenomas: practical considerations in the implementation of the Bordeaux criteria. Pathology 2018;50:593-9. [PMID: 30149989 DOI: 10.1016/j.pathol.2018.05.003] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
7 Thoolen B, Ten Kate FJ, van Diest PJ, Malarkey DE, Elmore SA, Maronpot RR. Comparative histomorphological review of rat and human hepatocellular proliferative lesions. J Toxicol Pathol 2012;25:189-99. [PMID: 22988337 DOI: 10.1293/tox.25.189] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
8 Chu HH, Moon WS. β-catenin activated hepatocellular adenoma. Clin Mol Hepatol 2013;19:185-9. [PMID: 23837144 DOI: 10.3350/cmh.2013.19.2.185] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
9 Reizine E, Amaddeo G, Pigneur F, Baranes L, Legou F, Mulé S, Zegai B, Roche V, Laurent A, Rahmouni A, Calderaro J, Luciani A. Quantitative correlation between uptake of Gd-BOPTA on hepatobiliary phase and tumor molecular features in patients with benign hepatocellular lesions. Eur Radiol 2018;28:4243-53. [PMID: 29721686 DOI: 10.1007/s00330-018-5438-7] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 3.3] [Reference Citation Analysis]
10 Mounajjed T, Yasir S, Aleff PA, Torbenson MS. Pigmented hepatocellular adenomas have a high risk of atypia and malignancy. Mod Pathol 2015;28:1265-74. [PMID: 26205181 DOI: 10.1038/modpathol.2015.83] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.9] [Reference Citation Analysis]
11 Myers L, Ahn J. Focal Nodular Hyperplasia and Hepatic Adenoma: Evaluation and Management. Clin Liver Dis 2020;24:389-403. [PMID: 32620279 DOI: 10.1016/j.cld.2020.04.013] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
12 Oliveira S, Samba AK, Towbin AJ, Gupta A, Geller JI, Nathan JD, Kohli R. Incidental inflammatory adenoma with β-catenin activation in the setting of paediatric NASH. Pediatr Obes 2018;13:70-3. [PMID: 27780309 DOI: 10.1111/ijpo.12189] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
13 Thomeer MG, Willemssen FE, Biermann KK, El Addouli H, de Man RA, Ijzermans JN, Dwarkasing RS. MRI features of inflammatory hepatocellular adenomas on hepatocyte phase imaging with liver-specific contrast agents: Hepatobiliary MRI for Inflammatory Adenoma. J Magn Reson Imaging 2014;39:1259-64. [DOI: 10.1002/jmri.24281] [Cited by in Crossref: 32] [Cited by in F6Publishing: 29] [Article Influence: 3.6] [Reference Citation Analysis]
14 van Aalten SM, Thomeer MG, Terkivatan T, Dwarkasing RS, Verheij J, de Man RA, Ijzermans JN. Hepatocellular adenomas: correlation of MR imaging findings with pathologic subtype classification. Radiology. 2011;261:172-181. [PMID: 21875850 DOI: 10.1148/radiol.11110023] [Cited by in Crossref: 157] [Cited by in F6Publishing: 130] [Article Influence: 14.3] [Reference Citation Analysis]
15 Bröker ME, Ijzermans JN, van Aalten SM, de Man RA, Terkivatan T. The management of pregnancy in women with hepatocellular adenoma: a plea for an individualized approach. Int J Hepatol. 2012;2012:725735. [PMID: 23320183 DOI: 10.1155/2012/725735] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.2] [Reference Citation Analysis]
16 Bieze M, Bennink RJ, El-massoudi Y, Phoa SS, Verheij J, Beuers U, van Gulik TM. The use of 18F-fluoromethylcholine PET/CT in differentiating focal nodular hyperplasia from hepatocellular adenoma: a prospective study of diagnostic accuracy. Nuclear Medicine Communications 2013;34:146-54. [DOI: 10.1097/mnm.0b013e32835afe62] [Cited by in Crossref: 11] [Article Influence: 1.2] [Reference Citation Analysis]
17 Bioulac-Sage P, Balabaud C, Zucman-Rossi J. Will the pathomolecular classification of hepatocellular adenomas improve their clinical management? J Hepatol. 2011;55:8-10. [PMID: 21300118 DOI: 10.1016/j.jhep.2011.01.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
18 Larson BK, Guindi M. A Limited Immunohistochemical Panel Can Subtype Hepatocellular Adenomas for Routine Practice. Am J Clin Pathol 2017;147:557-70. [PMID: 28472207 DOI: 10.1093/ajcp/aqx010] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
19 Krause K, Tanabe KK. A Shifting Paradigm in Diagnosis and Management of Hepatic Adenoma. Ann Surg Oncol 2020;27:3330-8. [PMID: 32542565 DOI: 10.1245/s10434-020-08580-w] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
20 Kim H, Jang JJ, Kim DS, Yeom BW, Won NH. Clinicopathological analysis of hepatocellular adenoma according to new bordeaux classification: report of eight korean cases. Korean J Pathol 2013;47:411-7. [PMID: 24255628 DOI: 10.4132/KoreanJPathol.2013.47.5.411] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
21 Margolskee E, Bao F, de Gonzalez AK, Moreira RK, Lagana S, Sireci AN, Sepulveda AR, Remotti H, Lefkowitch JH, Salomao M. Hepatocellular adenoma classification: a comparative evaluation of immunohistochemistry and targeted mutational analysis. Diagn Pathol. 2016;11:27. [PMID: 26961851 DOI: 10.1186/s13000-016-0475-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
22 Zheng Z, Sze CW, Keng CT, Al-Haddawi M, Liu M, Tan SY, Kwek HL, Her Z, Chan XY, Barnwal B, Loh E, Chang KTE, Tan TC, Tan YJ, Chen Q. Hepatitis C virus mediated chronic inflammation and tumorigenesis in the humanised immune system and liver mouse model. PLoS One 2017;12:e0184127. [PMID: 28886065 DOI: 10.1371/journal.pone.0184127] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
23 Bioulac-Sage P, Taouji S, Le Bail B, Possenti L, Balabaud C. Value and limits of routine histology alone or combined with glutamine synthetase immunostaining in the diagnosis of hepatocellular adenoma subtypes on surgical specimens. Int J Hepatol. 2013;2013:417323. [PMID: 23509631 DOI: 10.1155/2013/417323] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
24 Doolittle DA, Atwell TD, Sanchez W, Mounajjed T, Hough DM, Schmit GD, Kurup AN. Safety and Outcomes of Percutaneous Biopsy of 61 Hepatic Adenomas. American Journal of Roentgenology 2016;206:871-6. [DOI: 10.2214/ajr.15.15301] [Cited by in Crossref: 7] [Article Influence: 1.2] [Reference Citation Analysis]
25 Franchi-Abella S, Branchereau S. Benign hepatocellular tumors in children: focal nodular hyperplasia and hepatocellular adenoma. Int J Hepatol. 2013;2013:215064. [PMID: 23555058 DOI: 10.1155/2013/215064] [Cited by in Crossref: 33] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
26 Ishida R, Yano Y, Yamamoto A, Yasutomi E, Hatazawa Y, Hayashi H, Shiomi Y, Gon H, Omiya S, Kanzawa M, Itoh T, Ueda Y, Kodama Y. Beta-catenin-activated hepatocellular adenoma in a male. Clin J Gastroenterol 2021;14:831-5. [PMID: 33651269 DOI: 10.1007/s12328-021-01372-z] [Reference Citation Analysis]
27 Fukusato T, Soejima Y, Kondo F, Inoue M, Watanabe M, Takahashi Y, Aso T, Uozaki H, Sano K, Sanada Y, Niki T. Preserved or enhanced OATP1B3 expression in hepatocellular adenoma subtypes with nuclear accumulation of β-catenin. Hepatol Res 2015;45:E32-42. [PMID: 25418671 DOI: 10.1111/hepr.12453] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
28 Thomeer MG, Broker M, Verheij J, Doukas M, Terkivatan T, Bijdevaate D, De Man RA, Moelker A, IJzermans JN. Hepatocellular adenoma: when and how to treat? Update of current evidence. Therap Adv Gastroenterol. 2016;9:898-912. [PMID: 27803743 DOI: 10.1177/1756283x16663882] [Cited by in Crossref: 29] [Cited by in F6Publishing: 11] [Article Influence: 4.8] [Reference Citation Analysis]
29 Castain C, Sempoux C, Brunt EM, Causse O, Heitzmann A, Hernandez-prera JC, Le Bail B, Schirmacher P, Thung SN, Balabaud C, Bioulac-sage P. Coexistence of inflammatory hepatocellular adenomas with HNF1α-inactivated adenomas: is there an association? Histopathology 2014;64:890-5. [DOI: 10.1111/his.12326] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.9] [Reference Citation Analysis]
30 Deniz K, Umetsu SE, Ferrell L, Yılmaz F, Güllüoğlu M, Sağol Ö, Doğusoy GB, Kırımlıoğlu H, Turhan N, Doran F, Kepil N, Çelikel ÇA, Nart D, Özgüven BY, Ceyran B, Karadağ N, Kır G, Erden E, Yılmaz G, Akyol G. Hepatocellular adenomas in the Turkish population: reclassification according to updated World Health Organization criteria. Histopathology 2021;79:23-33. [PMID: 33406290 DOI: 10.1111/his.14330] [Reference Citation Analysis]
31 Chopinet S, Cauchy F, Hobeika C, Beaufrère A, Poté N, Farges O, Dokmak S, Bouattour M, Ronot M, Vilgrain V, Paradis V, Soubrane O. Long-term outcomes following resection of hepatocellular adenomas with small foci of malignant transformation or malignant adenomas. JHEP Rep 2021;3:100326. [PMID: 34368664 DOI: 10.1016/j.jhepr.2021.100326] [Reference Citation Analysis]
32 Bioulac-sage P, Cubel G, Taouji S, Scoazec J, Leteurtre E, Paradis V, Sturm N, Van Nhieu JT, Wendum D, Bancel B, Ramos J, Paraf F, Saint Paul MC, Michalak S, Fabre M, Guettier C, Le Bail B, Zucman-rossi J, Balabaud C. Immunohistochemical Markers on Needle Biopsies Are Helpful for the Diagnosis of Focal Nodular Hyperplasia and Hepatocellular Adenoma Subtypes. American Journal of Surgical Pathology 2012;36:1691-9. [DOI: 10.1097/pas.0b013e3182653ece] [Cited by in Crossref: 89] [Cited by in F6Publishing: 25] [Article Influence: 8.9] [Reference Citation Analysis]
33 Scoazec JY. Hepatocellular adenomas: one step beyond. Gut 2019;68:1140-2. [PMID: 30967413 DOI: 10.1136/gutjnl-2019-318299] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
34 Nault JC, Zucman Rossi J. Molecular classification of hepatocellular adenomas. Int J Hepatol. 2013;2013:315947. [PMID: 23401783 DOI: 10.1155/2013/315947] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 2.1] [Reference Citation Analysis]
35 Chang CY, Hernandez-Prera JC, Roayaie S, Schwartz M, Thung SN. Changing epidemiology of hepatocellular adenoma in the United States: review of the literature. Int J Hepatol. 2013;2013:604860. [PMID: 23509632 DOI: 10.1155/2013/604860] [Cited by in Crossref: 56] [Cited by in F6Publishing: 42] [Article Influence: 6.2] [Reference Citation Analysis]
36 Oudmaijer CAJ, Berk KA, van der Louw EJTM, de Man R, van der Lelij AJ, Hoeijmakers JHJ, IJzermans J. KETOgenic diet therapy in patients with HEPatocellular adenoma: study protocol of a matched interventional cohort study. BMJ Open 2022;12:e053559. [PMID: 35168973 DOI: 10.1136/bmjopen-2021-053559] [Reference Citation Analysis]
37 Thapar M, Grapp O, Fisher C. Management of hepatic adenomatosis. Curr Gastroenterol Rep 2015;17:12. [PMID: 25740249 DOI: 10.1007/s11894-015-0434-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
38 Védie AL, Sutter O, Ziol M, Nault JC. Molecular classification of hepatocellular adenomas: impact on clinical practice. Hepat Oncol 2018;5:HEP04. [PMID: 30302195 DOI: 10.2217/hep-2017-0023] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
39 Gupta S, Naini BV, Munoz R, Graham RP, Kipp BR, Torbenson MS, Mounajjed T. Hepatocellular Neoplasms Arising in Association With Androgen Use. Am J Surg Pathol 2016;40:454-61. [PMID: 26685086 DOI: 10.1097/PAS.0000000000000576] [Cited by in Crossref: 20] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
40 Bieze M, Bioulac-Sage P, Verheij J, Balabaud C, Laurent C, van Gulik TM. Hepatocellular adenomas associated with hepatic granulomas: experience in five cases. Case Rep Gastroenterol 2012;6:677-83. [PMID: 23185149 DOI: 10.1159/000343434] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
41 Vanhooymissen IJ, Thomeer MG, Braun LM, Gest B, van Koeverden S, Willemssen FE, Hunink M, De Man RA, Ijzermans JN, Dwarkasing RS. Intrapatient Comparison of the Hepatobiliary Phase of Gd-BOPTA and Gd-EOB-DTPA in the Differentiation of Hepatocellular Adenoma From Focal Nodular Hyperplasia: Hepatobiliary Phase of Two Contrast Agents. J Magn Reson Imaging 2019;49:700-10. [DOI: 10.1002/jmri.26227] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.5] [Reference Citation Analysis]
42 Nault JC, Paradis V, Cherqui D, Vilgrain V, Zucman-Rossi J. Molecular classification of hepatocellular adenoma in clinical practice. J Hepatol. 2017;67:1074-1083. [PMID: 28733222 DOI: 10.1016/j.jhep.2017.07.009] [Cited by in Crossref: 71] [Cited by in F6Publishing: 60] [Article Influence: 14.2] [Reference Citation Analysis]
43 Bioulac-sage P, Cubel G, Balabaud C. Pathological diagnosis of hepatocellular adenoma in clinical practice. Diagnostic Histopathology 2011;17:521-9. [DOI: 10.1016/j.mpdhp.2011.10.007] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
44 Nault JC, Bioulac-Sage P, Zucman-Rossi J. Hepatocellular benign tumors-from molecular classification to personalized clinical care. Gastroenterology. 2013;144:888-902. [PMID: 23485860 DOI: 10.1053/j.gastro.2013.02.032] [Cited by in Crossref: 199] [Cited by in F6Publishing: 145] [Article Influence: 22.1] [Reference Citation Analysis]
45 van Aalten SM, Witjes CD, de Man RA, Ijzermans JN, Terkivatan T. Can a decision-making model be justified in the management of hepatocellular adenoma? Liver Int. 2012;32:28-37. [PMID: 22098685 DOI: 10.1111/j.1478-3231.2011.02667.x] [Cited by in Crossref: 35] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
46 Nault JC, Couchy G, Balabaud C, Morcrette G, Caruso S, Blanc JF, Bacq Y, Calderaro J, Paradis V, Ramos J, Scoazec JY, Gnemmi V, Sturm N, Guettier C, Fabre M, Savier E, Chiche L, Labrune P, Selves J, Wendum D, Pilati C, Laurent A, De Muret A, Le Bail B, Rebouissou S, Imbeaud S, Bioulac-Sage P, Letouzé E, Zucman-Rossi J; GENTHEP Investigators. Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation. Gastroenterology 2017;152:880-894.e6. [PMID: 27939373 DOI: 10.1053/j.gastro.2016.11.042] [Cited by in Crossref: 168] [Cited by in F6Publishing: 144] [Article Influence: 28.0] [Reference Citation Analysis]
47 Margonis GA, Ejaz A, Spolverato G, Rastegar N, Anders R, Kamel IR, Pawlik TM. Benign solid tumors of the liver: management in the modern era. J Gastrointest Surg 2015;19:1157-68. [PMID: 25560181 DOI: 10.1007/s11605-014-2723-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
48 Longerich T, Endris V, Neumann O, Rempel E, Kirchner M, Abadi Z, Uhrig S, Kriegsmann M, Weiss KH, Breuhahn K, Mehrabi A, Weber TF, Wilkens L, Straub BK, Rosenwald A, Schulze F, Brors B, Froehling S, Pellegrino R, Budczies J, Schirmacher P, Stenzinger A. RSPO2 gene rearrangement: a powerful driver of β-catenin activation in liver tumours. Gut 2019;68:1287-96. [PMID: 30901310 DOI: 10.1136/gutjnl-2018-317632] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 5.7] [Reference Citation Analysis]
49 van Aalten SM, de Man RA, IJzermans JN, Terkivatan T. Systematic review of haemorrhage and rupture of hepatocellular adenomas. Br J Surg. 2012;99:911-916. [PMID: 22619025 DOI: 10.1002/bjs.8762] [Cited by in Crossref: 107] [Cited by in F6Publishing: 94] [Article Influence: 10.7] [Reference Citation Analysis]
50 Thomeer MG, E Bröker ME, de Lussanet Q, Biermann K, Dwarkasing RS, de Man R, Ijzermans JN, de Vries M. Genotype-phenotype correlations in hepatocellular adenoma: an update of MRI findings. Diagn Interv Radiol 2014;20:193-9. [PMID: 24509184 DOI: 10.5152/dir.2013.13315] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
51 Fonseca S, Hoton D, Dardenne S, Annet L, Hubert C, Godecharles S, Jouret-Mourin A, Reding R, Otte JB, Rahier J, Gigot JF, Sempoux C. Histological and immunohistochemical revision of hepatocellular adenomas: a learning experience. Int J Hepatol 2013;2013:398308. [PMID: 23533787 DOI: 10.1155/2013/398308] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
52 Sempoux C, Balabaud C, Bioulac-Sage P. Malignant transformation of hepatocellular adenoma. Hepat Oncol. 2014;1:421-431. [PMID: 30190977 DOI: 10.2217/hep.14.14] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 2.0] [Reference Citation Analysis]
53 Kumagawa M, Matsumoto N, Watanabe Y, Hirayama M, Miura T, Nakagawara H, Ogawa M, Matsuoka S, Moriyama M, Takayama T, Sugitani M. Contrast-enhanced ultrasonographic findings of serum amyloid A-positive hepatocellular neoplasm: Does hepatocellular adenoma arise in cirrhotic liver? World J Hepatol 2016; 8(26): 1110-1115 [PMID: 27660679 DOI: 10.4254/wjh.v8.i26.1110] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
54 Sasaki M, Nakanuma Y. Overview of hepatocellular adenoma in Japan. Int J Hepatol 2012;2012:648131. [PMID: 22973519 DOI: 10.1155/2012/648131] [Cited by in Crossref: 23] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
55 Cristiano A, Dietrich A, Spina JC, Ardiles V, de Santibañes E. Focal nodular hyperplasia and hepatic adenoma: current diagnosis and management. Updates Surg 2014;66:9-21. [DOI: 10.1007/s13304-013-0222-3] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
56 Roncalli M, Sciarra A, Tommaso LD. Benign hepatocellular nodules of healthy liver: focal nodular hyperplasia and hepatocellular adenoma. Clin Mol Hepatol 2016;22:199-211. [PMID: 27189732 DOI: 10.3350/cmh.2016.0101] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
57 Balabaud C, Al-Rabih WR, Chen PJ, Evason K, Ferrell L, Hernandez-Prera JC, Huang SF, Longerich T, Park YN, Quaglia A. Focal Nodular Hyperplasia and Hepatocellular Adenoma around the World Viewed through the Scope of the Immunopathological Classification. Int J Hepatol. 2013;2013:268625. [PMID: 23691331 DOI: 10.1155/2013/268625] [Cited by in Crossref: 36] [Cited by in F6Publishing: 23] [Article Influence: 4.0] [Reference Citation Analysis]
58 Sasaki M, Yoneda N, Kitamura S, Sato Y, Nakanuma Y. Characterization of hepatocellular adenoma based on the phenotypic classification: The Kanazawa experience. Hepatol Res. 2011;41:982-988. [PMID: 21883740 DOI: 10.1111/j.1872-034x.2011.00851.x] [Cited by in Crossref: 43] [Cited by in F6Publishing: 18] [Article Influence: 3.9] [Reference Citation Analysis]
59 Grieser C, Steffen IG, Kramme IB, Bläker H, Kilic E, Perez Fernandez CM, Seehofer D, Schott E, Hamm B, Denecke T. Gadoxetic acid enhanced MRI for differentiation of FNH and HCA: a single centre experience. Eur Radiol 2014;24:1339-48. [PMID: 24658870 DOI: 10.1007/s00330-014-3144-7] [Cited by in Crossref: 33] [Cited by in F6Publishing: 35] [Article Influence: 4.1] [Reference Citation Analysis]
60 Agostini CH, Ribeiro OD, Fernandes A, Caroli-bottino A, Pannain VL. Relevance of morphological features for hepatocellular adenoma classification in pathology practice. Surg Exp Pathol 2020;3. [DOI: 10.1186/s42047-020-00061-4] [Reference Citation Analysis]
61 Calderaro J, Labrune P, Morcrette G, Rebouissou S, Franco D, Prévot S, Quaglia A, Bedossa P, Libbrecht L, Terracciano L. Molecular characterization of hepatocellular adenomas developed in patients with glycogen storage disease type I. J Hepatol. 2013;58:350-357. [PMID: 23046672 DOI: 10.1016/j.jhep.2012.09.030] [Cited by in Crossref: 105] [Cited by in F6Publishing: 94] [Article Influence: 10.5] [Reference Citation Analysis]
62 Sempoux C, Chang C, Gouw A, Chiche L, Zucman-Rossi J, Balabaud C, Bioulac-Sage P. Benign hepatocellular nodules: what have we learned using the patho-molecular classification. Clin Res Hepatol Gastroenterol. 2013;37:322-327. [PMID: 23876350 DOI: 10.1016/j.clinre.2013.04.008] [Cited by in Crossref: 24] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]